S
Stephan R. Targan
Researcher at Cedars-Sinai Medical Center
Publications - 577
Citations - 61849
Stephan R. Targan is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 108, co-authored 545 publications receiving 58069 citations. Previous affiliations of Stephan R. Targan include University of Münster & Mount Sinai Hospital, Toronto.
Papers
More filters
Journal ArticleDOI
Genetic markers may predict disease behavior in patients with ulcerative colitis.
M. Roussomoustakaki,Jack Satsangi,Ken I. Welsh,Edouard Louis,Greg Fanning,Stephan R. Targan,Carol J. Landers,Derek P. Jewell +7 more
TL;DR: Genetic markers may predict disease behavior in ulcerative colitis in patients undergoing surgery for their colitis using HLA DRB1 and DQB1 genotyping.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R. Targan,Brian G. Feagan,Severine Vermeire,Remo Panaccione,Gil Y. Melmed,Carol J. Landers,Dalin Li,Chris B. Russell,Richard Newmark,Nan Zhang,Yun Chon,Yi-Hsiang Hsu,Shao-Lee Lin,Paul Klekotka +13 more
TL;DR: Treatment with brodalumab resulted in a disproportionate number of cases of worsening CD in patients with active CD and no evidence of meaningful efficacy, and analyses did not suggest additional safety risks of brodalUMab beyond worsening of CD symptoms in patientsWith active CD.
Journal ArticleDOI
TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.
Hidetoshi Takedatsu,Kathrin S. Michelsen,Bo Wei,Carol J. Landers,Lisa S. Thomas,Deepti Dhall,Jonathan Braun,Stephan R. Targan +7 more
TL;DR: It is revealed that TL1A is an important modulator in the development of chronic mucosal inflammation by enhancing T(H)1 and T( H)17 effector functions.
Journal ArticleDOI
Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.
Eric A. Vasiliauskas,Eric A. Vasiliauskas,Joseph A. Church,Neil S. Silverman,Mary J. Barry,Stephan R. Targan,Stephan R. Targan,Marla Dubinsky,Marla Dubinsky +8 more
TL;DR: Clinically significant infliximab levels were detected in the offspring and the timing of infusions to minimize antibody transfer to the fetus might be an important strategic consideration when therapeutic antibodies are used in pregnancy.
Journal ArticleDOI
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
Marla Dubinsky,Eric A. Vasiliauskas,Hardeep Singh,Maria T. Abreu,Kostas A. Papadakis,Tram Tran,Paul Martin,John M. Vierling,Stephen A. Geller,Stephan R. Targan,Fred Poordad +10 more
TL;DR: It is suggested that 6-TG should not be considered as therapy for patients with IBD because of the weak association with nodular regenerative hyperplasia of the liver and portal hypertension.